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Abstract 
 
An important hallmark of tumor cells is their resistance to apoptosis. Apoptosis is a 
tightly regulated cellular response that ultimately results in the elimination and 
disposal of unwanted or damaged cells. Apoptosis is brought about by a family of 
proteases known as the caspases, the activity of which is responsible for the 
organized destruction of the cell. Each step of the apoptotic signaling cascade is 
under stringent control. Apoptotic signaling can be regulated at the apical point of the 
apoptotic cascade by controlling the translation of death-inducing signals into 
proteolytic activity or more critically by direct modulation of proteolytic activity of 
caspases. The later is modulated by direct interaction of caspases with members of 
the inhibitor of apoptosis protein (IAP) family, the most studied one, X-linked IAP 
(XIAP), has evolved to potently inhibit the enzymatic activity of mammalian caspases. 
By efficiently inhibiting caspases XIAP has been shown to block apoptosis and 
described as a factor conferring resistance against different chemotherapeutic drugs 
(chemoresistant factor) in a variety of tumor cells. Furthermore, elevated XIAP 
expression has been frequently observed in several tumor tissues and XIAP targeting 
sensitizes diverse tumor cell lines for chemotherapeutic agents underlining the role of 
XIAP in tumor chemoresistance. However, by generating stable cell lines 
overexpressing XIAP the data provided show that XIAP overexpression alone does 
not generate a chemoresistant phenotype. Experiments evaluating both XIAP 
overexpression and stable knock-down of SMAC, a critical regulator of XIAP, show 
that XIAP action as a chemoresistant factor is tightly controlled by SMAC. In contrast 
to Bcl2 that acts as a mitochondrial gatekeeper, XIAP does not alter mitochondrial 
functions. Cytostatic drugs readily induce release of SMAC in cells with functionally 
intact mitochondria independent of caspase action, thereby completely neutralizing 
the anti-apoptotic action of even overexpressed XIAP. Although increased cytotoxic 
activity by different cytostatic drugs was observed, XIAP targeting failed to restore 
chemosensitivity in chemoresistant Hodgkin Lymphoma-derived cell lines indicating 
limited involvement of XIAP in chemoresistance. Unlike chemotherapeutic agents, 
XIAP targeting resulted in complete reactivation of the apoptotic machinery in 
response to grzB treatment regardless of mitochondrial functional state. These data 
demonstrated for the first time that it is essential to assess the mitochondrial capacity 
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to release SMAC as well as the expression levels of both XIAP and SMAC in order to 
predict the chemosensitivity of particular tumours, a relationship that has not 
previously been recognised.  
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Zusammenfassung 
 
Ein wichtiges Merkmal von Krebszellen ist ihre Apoptoseresistenz, welche wesentlich 
zu der neoplastischen Proliferation sowie der Resistenz gegenüber dem 
Immunsystem und der Chemotherapie beiträgt. Bei der Apoptose handelt es sich um 
eine streng regulierte zelluläre Reaktion, deren charakteristische Merkmale unter 
anderem die Veränderungen der Plasmamembran (membrane blebbing) und die 
Kondensierung des Zellkernes (den Abbau der genomischen DNA) beinhalten. Dabei 
ist die Aktivität einer Familie von Proteasen, die als Caspasen bekannt sind, 
essentiell für die systematische Eliminierung der Zelle. Die Initiation der Apoptose 
erfolgt über die Signaltransduktion eines apoptotischen Stimulus zur proteolytischen 
Prozessierung/Aktivierung der Initiatorcaspasen (Caspase-8 und -9), die ihrerseits 
die Effektorcaspasen (Caspase-3, -6 und -7) proteolytisch aktivieren. Die Aktivierung 
von Caspasen kann über mindestens zwei Apoptosesignalwege erfolgen: Der erste 
Signalweg wird durch die Aktivierung der Todesrezeptoren auf der Zelloberfläche 
durch die Bindung ihrer spezifischen Liganden eingeleitet, was zur Rekrutierung und 
Aktivierung von Caspase-8 führt. Im zweiten Signalweg spielen die Mitochondrien 
eine zentrale Rolle. Die Aktivierung des mitochondrialen Apoptosesignalweges führt 
zur Permeabilisierung der äußeren mitochondrialen Membran (mitochondrial outer 
membrane permeabilization; MOMP) und dadurch zur Freisetzung von 
proapoptotischen Proteinen wie Cytochrome c aus dem Intermembranraum 
(intermembrane space; IMS) ins Zytosol. Zusammen mit den zytosolischen 
Komponenten Apaf-1 und Caspase-9 initiiert es die Formierung des Apoptosoms 
wodurch die Aktivierung von Caspase-9 in Abhängigkeit von ATP-Verbrauch erfolgt.  
 
Aufgrund der immensen Bedeutung der Apoptose und der damit verbundenen 
Konsequenzen für die Zelle wird jeder Schritt in der apoptotischen Signalkaskade 
strengstens kontrolliert. Die Funktion von Caspasen als Haupteffektoren der 
Apoptose kann mittels verschiedener (Adapter-) Proteine reguliert werden, die 
entweder direkt oder indirekt die proteolytische Aktivierung und Aktivität der 
Caspasen beeinflussen und somit die Apoptose modulieren können. Die Mitglieder 
der Inhibitor of Apoptosis Protein (IAP) Familie können die Apoptose durch die 
direkte Interaktion mit den Caspasen regulieren. Das am besten erforschte Protein 
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dieser Familie, das X-chromosomale IAP (XIAP), ist in der Lage die enzymatische 
Aktivität von Caspasen effizient zu hemmen und gilt als der potenteste zelluläre 
Caspaseinhibitor. Weiterhin wird die Funktion von IAPs durch verschiedene zelluläre 
Proteine moduliert, die IAPs binden und damit deren inhibitorische Funktion 
aufheben können. Der wohl bekannteste zelluläre Inhibitor von den IAPs ist der 
second mitochondrial derived activator of caspases (SMAC), der als inaktives, 
zytosolisches Protein translatiert wird. Die Reifung von SMAC erfolgt im 
Intermembranraum der Mitochondrien, wohin es mittels seiner NH2-terminalen 
mitochondrialen Zielsequenz (MTS) transloziert wird. Dort wird die MTS proteolytisch 
entfernt und dadurch das NH2-terminale AVPI-Motiv freigelegt, das für die Bindung 
und die Inhibition von IAPs essentiell ist. Während der Apoptose wird neben 
Cytochrome c unter anderem auch das maturierte SMAC ins Zytosol freigesetzt, wo 
es dann die IAPs inhibieren kann.  
 
Durch die direkte Interaktion und effiziente Inhibition von Caspasen wurde XIAP als 
ein anti-apoptotisches Protein identifiziert. Weiterhin wurde eine erhöhte Expression 
von XIAP in verschiedenen Tumorzellen beobachtet, die mit einem geringen 
Therapieerfolg assoziiert war. Darüber hinaus führte die Verminderung der 
Expression von XIAP mittels RNAi oder die Blockade seiner inhibitorischen Funktion, 
z. B. durch SMAC, zu einer erhöhten Suszeptibilität gegenüber Chemotherapeutika 
in einer Vielzahl von Tumorzellen. Somit wurde XIAP in den vergangenen Jahren als 
ein viel versprechendes Therapieziel in malignen Erkrankungen identifiziert.  
 
In der vorliegenden Arbeit wurde die Bedeutung von XIAP in der Chemoresistenz 
von Tumoren untersucht. Dabei wurden stabile Zelllinien mit Modifikation der 
Expression von XIAP und SMAC etabliert und mit verschiedenen Zytostatika 
behandelt. Im Gegensatz zum aktuellen Modell über die Rolle von XIAP bei der 
Resistenz gegenüber chemotherapeutischen Substanzen zeigen diese Daten, dass 
eine Überexpression von XIAP allein keine Chemoresistenz erzeugen kann. Alle hier 
getesteten konventionellen Zytostatika induzieren unabhängig von der 
Caspaseaktivität oder von XIAP die Freisetzung von SMAC aus den Mitochondrien 
und neutralisieren damit vollständig die antiapoptotische Wirkung von sogar 
überexpremiertem XIAP. Dahingegen führte ein stabiler knock-down von SMAC in 
der Kombination mit einer Überexpression von XIAP zu einer deutlichen 
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Chemoresistenz, was folglich die Funktion von XIAP als Chemoresistenzfaktor in der 
Abhängigkeit der Expression und der mitochondrialen Freisetzung von SMAC stellt. 
Die Analyse der Chemosensitivität von malignen Hodgkin Lymphom Zelllinien zeigt, 
dass der knock-down von XIAP in diesen Zellen zwar zu einer erhöhten 
Chemosuszeptibilität führt aber nicht vollständig den Apoptosesignalweg reaktivieren 
kann. Diese Beobachtungen lassen auf eine eher geringfügige Bedeutung der 
erhöhten XIAP Expression für die Prognose über die Tumor-Chemosuszeptibilität 
schließen.  
 
Diese Daten zeigen zum ersten Mal, dass es unerlässlich ist die mitochondriale 
Fähigkeit zur Freisetzung SMAC sowie die Expressionslevel von XIAP und SMAC zu 
berücksichtigen, um eine Vorhersage über die Chemosensitivität von Tumoren zu 
treffen - eine Beziehung zueinander, die bisher nicht anerkannt wurde. 
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Aberrations 
 
MOMP Mitochondrial Outer Membrane Permeabilization 
SMAC Second Mitochondrial derived Activator of Caspases 
IAP Inhibitor of Apoptosis Protein 
XIAP X-linked IAP 
Caspase Cysteinyl-Aspartate Specific ProteASE 
DISC Death Inducing Signaling Complex 
TNF-R Tumor Necrosis Factor Receptor 
FADD Fas Associated protein with Death Domain 
FLICE FADD-Like Interleukin-1β-Converting Enzyme 
Apaf1 Apoptosis Protease-Activating Factor 1 
AIF Apoptosis Inducing Factor 
BIR Baculovirus IAP Repeat 
HL Hodgkin Lymphoma 
H-RS cells Hodgkin-Reed/Sternberg cells 
STS Staurosporine 
ETO Etoposide 
DOX Doxorubicin 
VBL Vinblastine 
VCR Vincristine 
MTX Mitoxanthrone 
CIS cis-Platin 
SDS-PAGE Sodium Dodecyl Sulfate- PolyAcrylamide Gel Electrophoresis 
CVS Cristal Violet Staining 
XTT Cell proliferation kit II (Roche) 
IB Immune Blot 
IP Immune Precipitation 
PARP Poly-(ADP-Ribose) Polymerase 
grzB Granzyme B 
Ub Ubiquitin 
Pfu proliferating units 
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Introduction 
 
Apoptosis 
Life means death – homeostasis in complex organisms is maintained by the finely 
tuned balance between cellular regeneration and death. About 10 billion of our cells 
will die each day just to counter the numbers of new cells that arise through mitosis. 
A number of modes of cell death have been described so far, and it seems quite 
possible that others await discovery. Two major modes of cell death have been 
intensively investigated: Necrosis and apoptosis. Whereas necrosis describes the 
process of pathological cell death, where amongst other things the release of cellular 
material into the extracellular space occurs, eliciting an immune response and 
inflammation (Gallucci et al., 1999; Shi et al., 2000), apoptosis describes the 
physiological cell death, that is an orchestrated collapse of cells, which manifests in 
membrane blebbing, cell shrinkage, protein processing, chromatin condensation and 
DNA degradation (Kerr et al., 1972; Wyllie et al., 1980) followed by rapid engulfment 
of corpses by neighboring cells thus avoiding an inflammatory response. This type of 
programmed cell death has been discovered and rediscovered several times by 
various developmental biologists and cytologists, and has been named differently 
over the past two centuries (Lockshin and Zakeri, 2001). The term finally adopted is 
apoptosis, coined by Wyllie and colleagues in 1972 (Kerr et al., 1972). The authors 
noticed that apoptotic cells shared many morphological features, which were distinct 
from those observed in cells undergoing necrotic cell death, and they suggested that 
these shared morphological features might be the result of an underlying common, 
conserved, endogenous cell death program (reviewed by Goodlett and Horn, 2001; 
see also figure 1). 
For any multicellular organism, apoptosis plays an essential part in many processes 
of life, ranging from organ development to the purging of pathogen-infected cells from 
the body and the elimination of activated or auto-aggressive immune cells. Naturally, 
apoptosis has to be tightly regulated because uncontrolled cell death may result in 
developmental defects, autoimmune diseases, neurodegeneration or cancer. 
The ‘decision’ of a cell to die depends on the activity of many molecules that 
determine a cell's likelihood of activating its self-destruction program. Most of the 
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specific morphological changes that were observed in apoptotic cells upon apoptotic 
stimuli are mediated by a set of cysteine proteases. These death inducing proteases 
are homologous to each other, and are part of a large protein family known as 
caspases (Cysteinyl-Aspartate Specific ProteASE) (Alnemri et al., 1996). Caspases 
have diverse biological functions, including apoptosis, necrosis and inflammation. 
Thus far twelve caspases have been identified in humans, of which seven are key 
regulators of apoptosis. There are two types of apoptotic caspases: initiator (apical) 
caspases and effector (executioner) caspases (Kumar, 2007). Initiator caspases (-2, 
-8, -9, -10) proteolytically activate inactive pro-forms (zymogens) of effector caspases 
(-3, -6, -7).  In turn, effector caspases cleave other proteins within the cell resulting in 
the apoptotic process. These include approximately 400 substrates (Luthi and Martin, 
2007), such as lamins, kinases, DNA repair enzymes, and proteins involved in mRNA 
splicing, DNA replication, and cell survival, and this is presumed to trigger the 
morphological process of cell death defined as apoptosis (Kerr et al., 1972). The 
caspases themselves are activated by intrinsic and extrinsic apoptotic stimuli which 
will be discussed in the following. 
 
Figure 1: Structural changes of cells undergoing necrosis or apoptosis (taken from Goodlett et al., 
2001) 
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The two pathways of apoptosis 
Despite the cellular diversity of our body, all cells appear to activate the same basic 
elements of the death-inducing program. Two major apoptotic pathways have been 
identified, one responding to immune-mediated signals, dubbed the ‘‘extrinsic’’ 
pathway, and the other, the ‘‘intrinsic’’ pathway, is engaged following developmental 
cues or cellular stresses (Fig. 2). The extrinsic pathway is triggered through ligation 
of specific cell-surface death receptors, whereas the intrinsic pathway depends on 
Mitochondrial Outer Membrane Permeabilization (MOMP), which causes the release 
of apoptogenic factors from the intermembrane space into the cytoplasm. The 
eventual consequences of each pathway are similar, as they both result in the 
activation of members of the caspase cascade (Meier and Vousden, 2007). 
The extrinsic apoptotic pathway is initiated by the oligomerization, most probably the 
trimerization, of Tumor Necrosis Factor Receptor (TNF-R) family members, such as 
CD95, induced by ligation of their specific ligand. Receptor oligomerization results in 
formation of a complex of proteins associated with activated receptors. The so-called 
Death-Inducing Signaling Complex (DISC) is the first initiator complex after apoptotic 
induction. The death signal is propagated by a caspase cascade initiated by the 
activation of caspase-8, also called FLICE (FADD-Like Interleukin-1β-Converting 
Enzyme), at the DISC followed by a rapid cleavage of executioner caspases, like 
caspase-3 and other caspases, which eventually cleave vital substrates in the cell 
(Ashkenazi and Dixit, 1998; Kischkel et al., 1995; Krammer, 2000). 
The intrinsic apoptotic pathway involves mitochondria and results in the release of 
cytochrome c, which subsequently initiates the caspase activation. The released 
cytochrome c together with the Apoptosis Protease-Activating Factor 1 (Apaf-1) and 
procaspase-9 in the cytoplasm forms the apoptosome, the other initiator complex of 
apoptosis (Li et al., 1997; Saleh et al., 1999). This apoptosome complex in turn 
activates downstream executioner caspases, like caspase-3, -6 and -7 (Green and 
Reed, 1998; Li et al., 1997; Reed et al., 1998).  
Introduction 
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The role of mitochondria in apoptosis 
Morphological, biochemical, and molecular genetic studies have shown that 
mitochondria are the convergence point for diverse signaling cascades initiated by 
cellular damage. In addition to being crucial for energy production and essential 
metabolic pathways, mitochondria also play key roles in executing the apoptotic 
program. The mitochondrial check point permits cells to arrest in the cell cycle in 
order to repair/restore cellular function after chromosomal damage or may allow cells 
to undergo apoptosis upon overwhelming, persistent, or severe damage (Green and 
Figure 2: The two pathways of apoptosis. The extrinsic pathway of apoptosis is initialized by ligand 
binding to the death receptors (DR; i. e. CD95L to CD95) resulting in activation of the DR. To the 
active DR several proteins are recruited forming together the death inducing signaling complex 
(DISC). This platform recruits and activated the initiator caspase-8, following activation of the 
executioner caspase-3 which leads to apoptosis. The application of cytostatic drugs or UV treatment 
leads to cellular stress which induces the intrinsic apoptotic pathway. Herein the mitochondria 
become activated resulting in mitochondrial outer membrane permeabilization (MOMP). One of the 
proteins released from mitochondria after MOMP is cytochrome c which is necessary for forming the 
so called apoptosome together with other factors such as the initiator caspase-9, Apaf-1 and ATP, 
leading to the activation of caspase-9 which in turn activates caspase-3. As a further regulation point, 
the inhibitor of apoptosis protein (IAP) XIAP is able to bind both caspase-3 and caspase-9 and inhibit 
apoptosis. To brake this blockade another protein, the second derived mitochondrial activator of 
caspases (SMAC), is also released from mitochondria while MOMP. SMAC binds XIAP and inhibits it 
in its function, resulting in ongoing apoptosis. 
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Kroemer, 2004). The mitochondria act as pivotal decision centers, because they 
respond to apoptotic stimuli with Mitochondrial Outer Membrane Permeabilization 
(MOMP), releasing death-promoting factors from their intermembrane space into the 
cytosol. The release of cytochrome c from mitochondria couples these organelles to 
a pathway for caspase activation and apoptosis (Matsuyama and Reed, 2000; Reed 
and Kroemer, 2000). In addition to cytochrome c other mitochondrial pro-apoptotic 
factors are released, such as SMAC/DIABLO, which antagonizes the inhibitory effect 
of the Inhibitors Of Apoptosis (IAP) (Du et al., 2000; Verhagen et al., 2000), 
Apoptosis Inducing Factor (AIF), a flavoprotein with potent but relatively mysterious 
apoptotic activity (Lorenzo et al., 1999) and Omi/HtrA2, a serine protease which 
interacts and inhibits the X-linked Inhibitor Of Apoptosis Protein (XIAP) and enhances 
caspase activity (Hegde et al., 2002). 
The apoptotic activity of mitochondria is known to be regulated by the family of Bcl2 
proteins. The Bcl2 proteins, which have either pro- or anti-apoptotic activity, have 
been studied intensively over the past decade owing to their importance in the 
regulation of apoptosis, tumorigenesis and cellular responses to anti-cancer therapy 
(Youle and Strasser, 2008).  
 
Bcl2-family proteins with opposing apoptotic activities 
This protein family was named after the founding member of the family, which was 
isolated as a gene involved in follicular B cell lymphoma (Tsujimoto et al., 1985). The 
Bcl-2 family is comprised of well over a dozen proteins, which have been classified 
into three functional groups (Youle and Strasser, 2008). The key feature of the 
members of group I, such as BCL-2, BCL-XL, BCL-W, MCL1, BCL-B (also known as 
BCL-2L10) and A1 (also known as BCL-2A1) is that they all possess anti-apoptotic 
activity and protect cells from death. In contrast, group II consists of Bcl-2 family 
members with pro-apoptotic activity. Members of this group, including Bax, Bak and 
BOK (also known as MTD), have a similar overall structure to group I proteins, but 
promote apoptosis. It appears that the pro-apoptotic family members like Bax and 
Bak are crucial for initiating MOMP and their function is tightly controlled by anti-
apoptotic Bcl2 members. In apoptotic cells, Bax and Bak undergo a conformational 
change, oligomerize and gain their pro-apoptotic activity by triggering the release of 
cytochrome c/SMAC. Group III consists of a large and diverse collection of proteins 
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including BAD, BIK (also known as BLK or NBK), BID, HRK (also known as Death 
Protein-5 (DP5)), BIM (also known as BOD), BMF, NOXA and PUMA (also known as 
BBC3) whose only common feature is the presence of the 12–16-amino-acid BH3 
domain (Adams and Cory, 1998). Through their conserved BH3 domain these 
proteins can bind and regulate the activity of BCL-2 proteins. Recent evidence 
indicates that BH3-only proteins de-repress BAX and BAK by direct binding and 
inhibition of BCL-2 and other anti-apoptotic family members. By contrast, an 
opposing model postulates direct activation of BAX and BAK by some BH3-only 
proteins (specifically BIM, tBID and PUMA) (Youle, 2007). 
  
IAPs 
The cytosolic Inhibitor of Apoptosis Proteins (IAPs) are the key regulators of caspase 
activity in the cell. Both, the initiator as well as the effector caspases, can be 
regulated by IAP binding, inhibiting the caspase activity.  
The first members of the IAP family identified in 1993, were the baculoviral IAPs Cp-
IAP and Op-IAP, that had a cytoprotective effect by inhibiting virus induced apoptotic 
pathways in their target cells (Clem and Miller, 1994; Crook et al., 1993). The 
common structural feature of these IAPs is a motif termed the Baculovirus IAP 
Repeat (BIR) that is required for the cytoprotective function of IAPs. Subsequently, 
host proteins containing BIR domains have been identified in a wide range of lower 
and higher eukaryotic species, from yeast to mammals (Deveraux and Reed, 1999). 
The first human IAP identified was the Neuronal Apoptosis Inhibitory Protein (NAIP), 
involved in Spinal Muscular Atrophy (SMA), a neurodegenerative disorder (Liston et 
al., 1996; Roy et al., 1995). Further human IAPs including c-IAP-1/HIAP-2/hMIHB, c-
IAP-2/HIAP-1/hMIHC, X-IAP/hILP/MIHA, survivin, BRUCE and ML-IAP were 
subsequently identified by sequence homology and examined for their anti-apoptotic 
capacity (Ambrosini et al., 1997; Duckett et al., 1996; Hauser et al., 1998; Hawkins et 
al., 1996; Hay et al., 1995; Rothe et al., 1995; Roy et al., 1995; Uren et al., 1996; 
Vucic et al., 2000). The fact that the BIR motif is shared by all IAP members, 
suggests a central role for this domain in interacting with conserved components of 
the apoptotic machinery (Fig. 3). 
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The most extensively studied family member, XIAP, is a particularly potent inhibitor of 
caspase activity. Biochemical characterization of XIAP revealed that the second BIR 
domain (BIR2) inhibits caspase-3 and caspase-7, whereas the third BIR domain 
(BIR3) inhibits caspase-9 (Deveraux et al., 1999; Deveraux et al., 1998; Deveraux et 
al., 1997). Further biochemical and structural studies have precisely mapped the 
XIAP elements required for caspase inhibition, showing that some of these elements 
are specific to XIAP and not conserved amongst the IAP family (Eckelman and 
Salvesen, 2006; Eckelman et al., 2006). Indeed XIAP is the only member of this 
family able to directly inhibit both the initiation and execution phase of the caspase 
cascade and has garnered the most attention (Fig. 4). 
In addition to caspase binding capability, it has been shown that some IAPs have a 
ubiquitin-E3-ligase activity and are able to catalyze their own ubiquitination in vitro 
(Yang and Li, 2000) and not surprisingly are able to catalyze the ubiquitination of 
Figure 3: Mammalian IAPs/BIRPs. Alternative designations are shown in parentheses. The X-linked 
IAP (XIAP) is the best-characterized member of this family. BIR, Baculovirus IAP Repeat; CARD, 
Caspase-Recruitment Domain; ILP, IAP-Like Protein; MIHA, Mammalian IAP Homologue A; NAIP, 
Neuronal Apoptosis Inhibitory Protein (taken from Salvesen and Duckett, 2002). 
Figure 4: Interactions of caspase-3 and caspase-9 with XIAP. (A) The XIAP (in red) consists of three 
BIR domains; two of them (BIR2 & BIR3) harbors a binding groove. Additionally a RING domain is 
localized at the COOH-terminus. Caspase-3 and caspase-9 are shown as monomers in blue. (B) 
Inhibition of caspase 3 occurs after binding of the linker NH2-terminal of BIR2 from XIAP to caspase-
3 through sterical blockage of the catalytically center of caspase-3. (C) Caspase-9 is inhibited by 
binding to the binding groove of BIR3, resulting in avoidance of dimerization of caspase-9. 
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their substrates. XIAP in particular, can ubiquitinate caspase 3 (Suzuki et al., 2001b) 
and SMAC (MacFarlane et al., 2002) amongst other proteins. The ubiquitin-E3-ligase 
activity is associated with a RING domain that has been found in XIAP as well as 
other IAP family members (cIAP1 and cIAP2) that are subject to proteasomal 
degradation (Yang and Li, 2000).  
Furthermore, accumulating evidence suggest that XIAP has important roles in other 
cellular processes including morphogenesis (Olayioye et al., 2005), heavy metal 
homeostasis (Burstein et al., 2004; Mufti et al., 2006), NF-κB activation and TNF 
signalling (Gaither et al., 2007; Hofer-Warbinek et al., 2000), MAP kinase signaling 
(Lu et al., 2007), and neuronal differentiation (Yamaguchi et al., 1999), which may in 
fact prove to be more important in normal physiological processes.  
 
XIAP antagonists 
Several factors play critical roles in controlling the XIAP function by specifically 
interacting with and relieving its caspase-inhibitory effects. One of them is the XIAP 
Associated Factor 1 (XAF1), a cytosolic protein that upon binding to XIAP results in 
increased caspase 3 activity and sensitization to etoposide induced cell death even 
in XIAP overexpressing cells, suggesting an antagonizing effect of XAF1 in 
chemoresistance mediated by XIAP overexpression (Liston et al., 2001).  
Another XIAP binding protein, is the evolutionary conserved serine proteases HtrA2,  
(Hegde et al., 2002; Martins et al., 2002; Suzuki et al., 2001a; Verhagen et al., 2002) 
that in humans binds XIAP in a similar manner to SMAC, thereby facilitating caspase 
inhibition (Suzuki et al., 2001a). HtrA2 contains an NH2-terminal Mitochondrial 
Targeting Sequence (MTS), which is removed by proteolytic cleavage following 
translocation into the intermembrane space of mitochondria in the maturation 
process that exposes an NH2-terminal motif required for XIAP binding. In contrast to 
SMAC, HtrA2 can also promote cell death without membrane blebbing or apoptotic 
body formation that requires the serine protease activity (Suzuki et al., 2001a) and is 
not affected by caspase inhibitors (Hegde et al., 2002), suggesting two different 
mechanisms for cell death induction: Similar to SMAC, one mechanism depends on 
binding to and inhibition of XIAP and therefore results in increased caspase activity. 
The second mechanism relies on the serine protease activity of HtrA2, independently 
of caspase activity (Hegde et al., 2002; Suzuki et al., 2001a).  
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The ‘Second derived Mitochondrial Activator of Caspases’ (SMAC), also known as 
DIABLO, is the most popular and best investigated XIAP antagonist, promoting 
caspase activation by antagonizing IAPs (Du et al., 2000; Verhagen et al., 2000). 
SMAC is a nuclear-encoded, cytosolically translated protein which harbors an NH2-
terminal MTS similar to HtrA2, targeting it to the mitochondrion for translocation into 
the intermembranespace, where its MTS is proteolytically removed by the Inner 
Membrane Peptidase (IMP), resulting in the maturation of SMAC (Burri et al., 2005). 
After apoptotic activation of mitochondria, that results in MOMP, mature SMAC is 
released into the cytosol (Du et al., 2000; Verhagen et al., 2000). In its mature form 
SMAC reveals its NH2-terminal AVPI-sequence, which is an IAP Binding Motive 
(IBM), required for XIAP binding (Chai et al., 2000; Wu et al., 2000). With this AVPI-
sequence SMAC disrupt XIAPs caspase inhibitory activity (Liu et al., 2000) by 
binding to both the BIR2 and the BIR3 domain (Fig. 5), resulting in ongoing 
apoptosis. 
 
 
 
Apoptosis and Cancer 
The ability of tumor cell populations to expand in number is determined not only by 
the rate of cell proliferation but also by the rate of cell attrition. Apoptosis represents 
a major source of this attrition. The evidence is mounting, principally from studies in 
mouse models and cultured cells, as well as from descriptive analyses of biopsied 
stages in human carcinogenesis, that acquired resistance toward apoptosis is a 
hallmark of most and perhaps all types of cancer (Hanahan and Weinberg, 2000).  
The possibility that apoptosis serves as a barrier to cancer was first raised in 1972, 
when Kerr, Wyllie, and Currie described massive apoptosis in the cells populating 
rapidly growing, hormone-dependent tumors following hormone withdrawal. The 
discovery of the bcl-2 oncogene by its upregulation via chromosomal translocation in 
follicular lymphoma  (reviewed by Korsmeyer, 1992 and Strasser et al., 1990) and its 
recognition as having antiapoptotic activity (Vaux et al., 1988) opened up the 
Figure 5: Binding of SMAC (green) to XIAP (red). 
(A) Mature SMAC bears its NH2-terminal AVPI-
sequence like a horn on the surface.  
(B) Dimerized SMAC binds both the Bir2 and Bir3 
domain of XIAP, resulting in inhibition of XIAP 
function. 
Introduction 
19 
investigation of apoptosis in cancer at the molecular level. Other examples including 
inactivation of the p53 tumor suppressor protein, a component of the apoptotic 
signaling circuitry, which led to rapidly growing tumors containing low numbers of 
apoptotic cells (Symonds et al., 1994) strengthen the consensus that apoptosis is a 
major barrier to cancer that is broken during tumorigenesis. Collectively, these 
observations argue that altering components of the apoptotic machinery can 
dramatically affect the dynamics of tumor progression, providing a rationale for the 
inactivation of this machinery during tumor development. 
The most common malignant tumors of the lymphatic system are the Hodgkin 
Lymphomas (HL), identified by Sir Thomas Hodgkin in 1832. Typical for the Hodgkin 
lymphoma is the presence of giant abnormal cells, the Hodgkin-Reed/Sternberg cells 
(H-RS cells) in affected tissues (reviewed by Kuppers, 2003). In classical HL (cHL), 
malignant H-RS cells represent about 1% of the cell population in the affected lymph 
nodes (reviewed by Kuppers, 2003). Genetic and immunologic characterization of the 
H-RS revealed that they have rearranged B-cell receptor genes but no functional B-
cell receptors (Kanzler et al., 1996). In only minor cases (about 2% of the HL) T-cell 
receptor rearrangement has been observed (Muschen et al., 2000), suggesting a B-
cell origin for most classical HL cases. Nevertheless neither mature B-cell receptors 
nor T-cell receptors are presented on the surface of H-RS cells which would normally 
result in induction of apoptosis (Lam et al., 1997). The fact that H-RS cells survive 
without functional immune receptors suggests that H-RS cells are resistant to 
apoptosis. Indeed, a blockade of both the extrinsic and intrinsic apoptotic pathway is 
seen in H-RS cells. The extrinsic pathway has been shown to be blocked by the 
overexpression of cFlip, a caspase-8 inhibitor (Thomas et al., 2002), while the 
intrinsic pathway is blocked by deficient Bax activation and failure of the 
mitochondrial cytochrome c release (Kashkar et al., 2002; Kashkar et al., 2006). In 
addition, elevated expression of XIAP has been identified as a hallmark of HL cell 
lines and H-RS cells of primary tumor tissues (Kashkar et al., 2003) (Fig. 6). Classical 
HL is a fatal disease with 90% of untreated patients dying within 2 to 3 years. With 
modern polychemotherapy, more than 80% of patients suffering from cHL are cured. 
Despite this treatment success rate, the pathogenesis of cHL is still largely unknown. 
Dissolving the mechanisms by which H-RS cells escape apoptosis help to identify 
new strategies for anti cancer therapy. 
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Resistance to chemotherapeutic treatments and apoptosis 
Resistance to chemotherapy represents a major obstacle to cancer therapy. 
Although different forms of chemotherapy are aimed at a variety of biochemical 
targets, it is generally believed that chemotherapy kills cancer cells by induction of a 
final common pathway that leads to apoptosis (Houghton, 1999; Martin et al., 1997). 
The agents that are commonly used act by damaging cellular components including 
DNA (crosslinking DNA by cisplatin), and microtubules (vinblastine) or by inhibiting 
protein kinases to such an extent that apoptosis is induced. Thus, defects in the 
apoptotic machinery may result in chemoresistance (Lowe et al., 1994). 
Accumulating evidence suggest that the pathway involved in chemotherapeutic 
agent-induced apoptosis seems to be a consequence of damage to the mitochondria 
(Houghton, 1999), although the mechanisms that might induce these changes are 
not well understood. Correspondingly, elevated expression levels of Bcl2 have been 
identified as a chemoresistance factor (Reed, 1995). Activation of the transcription 
Figure 6: Expression of caspase activators and inhibitors in HL-derived B cell lines. (A) Equal 
amounts of proteins from total cell lysate of L1236, L591, L428, and KMH2 cells and of control B cells 
L1309 were subjected to SDS-PAGE and Western blot analysis. Proteins were detected using 
antibodies against Apaf-1 and XIAP. (B) XIAP expression in primary Hodgkin's lymphoma (HL) 
tissues. XIAP positivity in H-RS cells: + = very weak; ++ = weak; +++ = moderate; ++++ = strong 
staining. (C) Paraffin section immunohistochemistry of cases 3, 5, 6, 7, 10, and 11 of classical HL 
cases listed in Fig. 2 B. XIAP was stained using anti-XIAP specific mAb. There are strong (Nos. 5, 6, 
7, and 11) or moderate (Nos. 3 and 10) granular intracytoplasmic staining for XIAP in essentially all 
morphologically recognizable Hodgkin or Reed-Sternberg cells. Background lymphocytes are 
negative for XIAP staining (taken from Kashkar et al., 2003). 
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factor p53 is frequently associated with chemotherapy-induced apoptosis (Li et al., 
1998) and mutations in TP53 (the gene that encodes p53) are common in some 
cancers and lead to resistance to DNA-damaging agents (reviewed in Hersey and 
Zhang, 2001). Furthermore, the blockade of death receptor signaling (CD95 and 
CD95L) leads to apoptosis resistance in drug sensitive neuroblastoma cells (Fulda et 
al., 1997) and IAPs as potent caspase inhibitors, have also been suggested to play a 
role in drug resistance (reviewed by Schimmer et al., 2006). A range of diverse 
strategies are currently investigated in order to counter chemoresistance in cancer 
therapy. Targeting Bcl2 by antisense oligonucleotides (G3139 (Genasense), a Bcl2 
antisense phosphothioate oligonucleotide, is in phase I clinical trials) or by BH3 
mimetics approaches has been shown to suppress the oncogenic effect of anti-
apoptotic Bcl2 members and promises to be beneficial in patients suffering from 
malignancies (reviewed by Labi et al., 2008, Cotter et al., 1994 and Waters et al., 
2000). Targeting IAP by RNAi or SMAC mimetics have also been shown to sensitize 
tumor cells to apoptosis (reviewed by Schimmer et al., 2006, Li et al., 2004 and 
Nikolovska-Coleska et al., 2004). 
 
XIAP and Chemoresistance 
Given its role in apoptosis, there has been much interest in understanding the role of 
XIAP in cancer and evaluating XIAP as a therapeutic target. XIAP is overexpressed 
in malignant cells and, in certain patients, is associated with poor clinical outcome 
and has been viewed as the resistance factor for multiagent chemotherapy 
(Schimmer et al., 2006). From the discovery of XIAP in the second half of the 1990s, 
research on this unique IAP has been exponential giving us a detailed structural and 
mechanistic view of its activity in addition to abundant cell biological data. As a result, 
the development of potential drugs targeting XIAP has become possible offering 
targeted therapies to counteract cancer and overcome drug resistance. Several lines 
of evidence suggest that XIAP represents a promising target in cancer therapy: First, 
in vitro, XIAP overexpression confers resistance to different apoptotic stimuli 
(Schimmer et al., 2006). 
Second, elevated XIAP expression was reported in a variety of human cancers 
(Jaffer et al., 2007; Kashkar et al., 2003; Kluger et al., 2007; Krajewska et al., 2003; 
Lopes et al., 2007; Mizutani et al., 2007; Tamm et al., 2000; Tamm et al., 2004b) and 
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was associated with more aggressive tumor histology and decreased survival in 
patients (Mizutani et al., 2007; Tamm et al., 2004a; Tamm et al., 2004b). 
Finally, XIAP targeting by small molecules primarily designed to relieve XIAP-
mediated caspase-binding/inhibition or specific down-regulation of XIAP expression 
by RNA interference or anti-sense oligonucleotides induced cell death directly or 
synergistically with chemotherapeutic agents in a broad range of tumor cell lines in 
vitro and in tumor xenograft models (Arnt et al., 2002; Chawla-Sarkar et al., 2004; 
Fulda et al., 2002; Kashkar et al., 2007; Lima et al., 2004; McManus et al., 2004; 
Sasaki et al., 2000; Schimmer et al., 2004; Yang et al., 2003).  
However, recent data suggests that elevated XIAP expression in different tumor 
tissues is not an applicable prognostic marker for chemoresistant tumors and even 
associated with a more favorable clinical outcome (Ferreira et al., 2001; Hwang et al., 
2008; Seligson et al., 2007). Our knowledge about XIAP as a chemoresistance factor 
has been initially derived from caspase activity studies mainly using recombinant 
proteins in cell free systems (Deveraux et al., 1997) or from transient-overexpression 
studies of XIAP in intact cells (Duckett et al., 1998). Accordingly, the results obtained 
are limited in describing the capacity of XIAP to inhibit cell death in a living cell and 
fail to properly examine the potency of XIAP in the context of regulatory circuits. The 
crucial event in chemotherapeutic drugs-induced apoptosis is the mitochondrial outer 
membrane permeabilization with the subsequent release of multiple pro-apoptotic 
factors including cytochrome c and SMAC, initiating caspase proteolytic activity and 
regulating XIAP function, respectively. Thus, the physiological impact of XIAP on 
caspase activity is further determined by mitochondria and mitochondrial SMAC, a 
phenomenon which is completely disregarded in the initial previous works. 
 
Aim of the study 
 
From the discovery of XIAP in the second half of the 1990s, research on this unique 
IAP has been exponential giving us a detailed structural and mechanistic view of its 
activity in addition to abundant cell biology data (Eckelman et al., 2006). The aim of 
this study is to investigate the role of XIAP in tumor chemoresistance by stably 
modifying the expression level of XIAP and XIAP-antagonists in HeLa cell lines. The 
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impact of these findings will be further investigated in Hodgkin-Lymphoma tumor cell 
lines with elevated XIAP expression and defective apoptotic machinery.  
 
Methods 
24 
Methods 
Cell lines and cell culture  
HeLa, HeLa-Bcl2 and HeLa-mycXIAP (Kashkar et al., 2007; Kashkar et al., 2005) cell 
lines were cultured in DMEM and Jurkat, Jurkat-Bcl2, L591 and L428 cell lines 
(Kashkar et al., 2002) were cultured in VLE RPMI 1640 supplemented with 10% fetal 
calf serum, 2 mM L-glutamine, 100 µg/ml streptomycin, and 100 units/ml penicillin 
(Biochrom, Berlin, Germany). All chemicals were purchased from Sigma (Hamburg, 
Germany) unless indicated otherwise. Cells were treated with cytostatic agents at the 
indicated concentrations including Staurosporine (STS) (Alexis, Lausen, 
Switzerland), Etoposide (ETO), Doxorubicin (DOX), Mitoxanthrone (MTO), 
Vinblastine (VBL), Vincristine (VCR) and cis-Platin (CIS) incubated as indicated. 
Caspase activity was blocked by co-treatment of cells with 20 µM Z-VAD(Ome)-FMK 
(Alexis, Grünberg, Germany). 
GrzB/Ad (adenovirus)-mediated cell death was carried out as described previously by 
Goping et al. (Goping et al., 2003). In brief, 106 cells/ml were treated with 600 ng 
isolated human grzB (Alexis, Lausen, Switzerland) and 100 pfu Ad (a gift from Dr U. 
Protzer, University of Cologne/Germany) in serum-free media supplemented with 
0.1% (w/v) BSA. Cells were incubated for 4 to 5 hours at 37°C, then harvested and 
assessed for cell death by trypan blue staining. 
 
siRNA and lentiviral gene transfer  
To silence XIAP and SMAC expression, pENTR constructs were generated with a 
pair of oligonucleotides derived from XIAP and SMAC mRNAs (the sequence was 
obtained from Ambion Europe, Huntingdon, United Kingdom), which includes the 
unique N-19 target as described in pSUPER RNAi System Manual (OligoEngine, 
Seattle, WA). Three shRNA sequences were designed to down-regulate each gene. 
All shRNAs were examined in HeLa and HEK293 cells and the most potent shRNA 
was identified (data not shown) and stably expressed in cell lines using lentiviral 
gene transfer. The vector uses the polymerase-III H1-RNA gene promoter. After 
generating a pENTR clone, the pLenti6/V5DEST XIAPshRNA-, SMACshRNA- or 
scrshRNA-expressing vectors were created using LR recombination. The viral 
particles were produced according to the instructions of the manufacturers 
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(ViraPower Lentiviral expression system; Invitrogen). Cells were transiently 
transfected with pENTR vectors or transduced by the recombinant lentiviral 
constructs, and stable cell lines were generated by blasticidin (Invitrogen, Karlsruhe, 
Germany) selection.  
 
Sample preparation 
To extract whole cell lysates, cells were washed twice in cold (4°C) phosphate-
buffered saline (PBS), pelleted at 1.200xg for 3 min at 4°C and resuspended in 1 
volume of CHAPS lysis buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 1% CHAPS, 
complete protease inhibitor cocktail) on ice for 30 minutes. Samples were centrifuged 
at 14.000xg for 20 min at 4°C and supernatants (= whole cell lysates) as well as the 
resulting pellets (= nuclear extracts) were recovered.  
Poly(ADP-ribose) polymerase (PARP) cleavage was assessed after incubation of 
pellets in urea extraction buffer (50 mM Tris [pH 6.8], 6 M urea, 3% SDS, 10% 
glycerol, 0.00125% bromophenol blue, 5% 2-mercaptoethanol) denatured at 100°C 
for 10 minutes.  
For the preparation of cytosolic extracts about 107 cells were washed twice in cold 
(4°C) PBS and centrifuged at 1.200xg for 3 min at 4°C. The cells were then 
resuspended in 1 volume Buffer A (20 mM PIPES [pH 7.0], 50 mM KCl, 2 mM MgCl2, 
5 mM EGTA, 1 mM dithiothreitol, 10µM cytochalasin B) and incubated for 20 min on 
ice allowing to swell, following plasma membrane disruption by homogenization 
through a 27-gauge needle. The cell breakage was verified microscopically by trypan 
blue staining. After centrifugation at 14.000xg for 30 min at 4°C the supernatants (= 
cytosolic extract) was recovered and stored at -20°C. 
Protein concentration was determined by the bicinchoninic acid assay method (BCA-
Assay, Pierce) using BSA as a standard using an anthos ht2 (anthos Mikrosysteme 
GmbH, Krefeld, Germany)  
 
Immunoblotting 
Equal amounts of protein were separated by Sodium Dodecyl Sulfate–
PolyAcrylamide Gel Electrophoresis (SDS-PAGE) and transferred to nitrocellulose 
membrane (Protran 0.2 µm; Schleicher and Schuell) as previously described 
(Kashkar et al., 2002).  
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Rabbit polyclonal antiserum specific for Bax, mouse polyclonal antiserum specific for 
PARP and mouse monoclonal antibodies specific for XIAP, Bcl2, Bax clone 6A7 and 
cytochrome c were obtained from BD Laboratories (Heidelberg, Germany). Rabbit 
anti–caspase-3 and mouse anti-SMAC antibodies were obtained from Cell Signaling 
Technology (Beverly, MA). The mouse anti-GFP antibody was provided from 
Invitrogen (Karlsruhe, Germany). Affinity purified rabbit anti-cIAP1 and anti-cIAP2 
antibodies were obtained from R&D Systems (Wiesbaden-Nordenstadt, Germany). 
The mouse anti-actin antibody and the HorseRadish Peroxidase (HRP) conjugates of 
anti-rabbit and anti-mouse IgG were purchased from Sigma-Aldrich (Munich, 
Germany). The HRP-conjugated antibodies were used as secondary antibodies and 
chemiluminescent signals were detected by ECL (Pierce) on films (Amersham, GE 
Healthcare, Buckinghamshire, UK).  
 
Immunoprecipitation of active Bax 
Equal volumes of whole cell lysates (107 cells/ml) were used for immunoprecipitation. 
The KCl concentration of the cell lysates was adjusted to 150 mM, and all samples 
were brought to a final volume of 500 ml with CHAPS lysis buffer. Samples were 
rotated for 12 h at 4°C with 2 µg of monoclonal anti-Bax 6A7 antibody. Antigen-
antibody complexes were immobilized by rotation for 2 h at 4°C with GammaBind G 
Sepharose (Pharmacia Biotech). The complexes were pelleted (1 min, 14 000xg) and 
the supernatant removed. The complexes were then washed three times with the 
same buffer used for the immunoprecipitation and subjected to SDS - PAGE and 
immunoblotted as described above. 
 
Cell viability  
Cells (104 per well for HeLa, 105 per well for Jurkat/HL cells) were incubated in 96-
well plastic plates at 37°C in full medium and treated with the indicated 
concentrations of cytostatic agents and durations as indicated. Cell viability was 
assessed either by the XTT test (Cell Proliferation Kit II [XTT]; Roche Applied 
Sciences, Manheim, Germany) or Crystal Violet assay System (CVS). In XTT assay 
after treatments cells were incubated with the XTT reagents at 37°C for 4 hours 
according to the instructions of the manufacturer. The absorbance of the samples 
was measured with an enzyme-linked immunosorbent assay (ELISA) reader 
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(wavelength, 450 nm; reference wavelength, 620 nm). For CVS after treatment cells 
were washed twice with PBS, stained with crystal violet (0.2% w/v in 2% EtOH) and 
resolved by a mixture of 0,2 M sodium citrate and 100% EtOH (1:1 v/v). The 
colorimetric measurement was carried out at 595nm using a Tecan GENious Pro 
(Tecan, Crailsheim, Germany). All data are mean values from at least 3 different 
experiments in triplicate. Blank absorbance from wells that lacked cells was 
subtracted from that of the samples, and the difference between the absorbance is 
referred to as "% cell viability" (100% in untreated cells). 
 
Caspase activation 
For initiating caspase activation, 20 µg cell extracts were treated with either 
increasing amounts of horse heart cytochrome c as indicated and additional 1 mM 
dATP or 20 ng recombinant murine grzB with or without SMAC N-terminal peptide, 
H-AVPIAQK-OH (10 µM; Calbiochem) for 1 hour at 30°C. Alternative, whole cells 
where treated with increasing amounts of STS as indicated and cell extracts were 
prepared. For the following Caspase-3 activity measurement were 5 µg cell extracts 
in a total volume of 100 µl in caspase activation buffer (20 mM Pipes, 100 mM NaCl, 
1 mM EDTA, 0.1% CHAPS, 10 % sucrose, 10 mM dithiothreitol) used and the 
reaction was initiated by the addition of 100 µM Ac-DEVD–7-amino-4-
trifluoromethylcomarin (Ac-DEVD-AFC), following fluorescent readout at 400/505 nm 
using a Tecan GENious Pro (Tecan, Crailsheim, Germany). 
 
Immunofluorescence and fluorescence microscopy  
Cells were treated with 0.5 µM staurosporine or 5 µM doxorubicin for 8h. Cells were 
then fixed with 3% paraformaldehyde for 20 min, permeabilized with 0.1% saponin in 
PBS for 10 min, and blocked with 3% BSA and 0.1% saponin in PBS for 30 min. For 
immunostaining, cells were incubated with primary mouse anti-SMAC or anti 
Cytochrome c antibody for 1 h, washed with 0.1% saponin in PBS and then 
incubated with goat anti-mouse antibody conjugated with Alexaflour 568 (Molecular 
Probes) for 30 min. Nuclei were counterstained with Hoechst 33258 (10 mg/ml PBS) 
and mounted on glass slides and analyzed by a motorized inverted microscope 
(Olympus Ix81; Tokyo, Japan) using a 63x/1.40 numerical aperture Planapo oil 
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objective. Images were acquired using analy-SIS software (Soft Imaging System, 
Münster, Germany). 
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Results 
XIAP overexpression in HeLa cells does not confer resistance 
against cytostatic agents 
In order to characterize the role of XIAP as a chemoresistance factor, a HeLa cell line 
stably expressing myc-tagged XIAP (mycXIAP) was established (Fig. 7A and Fig. 
10). The cytoprotective potency of XIAP was analyzed in the HeLa-mycXIAP cell line 
after treatment with different cytostatic agents including staurosporine (STS), 
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doxorubicine (DOX), etoposide (ETO), mitoxantrone (MTO), vinblastin (VBL), and 
vincristin (VCR) and compared to HeLa and HeLa cell line overexpressing Bcl2 
(HeLa-Bcl2) as an established chemoresistance factor (Kashkar et al., 2005; Letai, 
2008; Reed, 1995) (Fig. 7A). Strikingly, overexpression of XIAP does not generate 
any cytoprotective effect nor does it confer an anti-apoptotic effect against cytostatic 
agents (Fig. 7B-C). All cytostatic agents exerted equal cytotoxic effects in HeLa and 
HeLa-mycXIAP cell lines as analyzed by two separate toxicity assays, XTT (Fig. 7B) 
and crystal violet staining (CVS) (Fig. 7C). Analysis of PARP cleavage to monitor the 
ongoing apoptotic process demonstrated the involvement of a functional apoptotic 
cascade in HeLa and HeLa-mycXIAP cell lines generating cleaved PARP upon 
cytostatic treatments (Fig. 7D). In contrast, Bcl2 overexpression markedly reduced 
cytotoxicity and completely abrogated the apoptotic capability of cells after different 
cytostatic drug treatments (Fig. 7B-D). 
 
 
Caspase-independent mitochondrial SMAC release in response to 
cytostatic agents regulates the anti-apoptotic potential of XIAP 
In order to investigate the caspase inhibitory potency of overexpressed XIAP in the 
HeLa-mycXIAP cell line, cytosolic extracts of intact HeLa cell lines were prepared 
and caspase activity was initiated by exogenously added cytochrome c and dATP 
(Kashkar et al., 2003). In contrast to HeLa cells cytochrome c-induced caspase-3 
activity was significantly impaired in cytosolic extracts derived from HeLa-mycXIAP 
cells demonstrating the caspase inhibitory potency of overexpressed mycXIAP. As 
the sensory centers of cytotoxic stresses, mitochondria promote caspase activity by 
releasing pro-apoptotic factors including cytochrome c and SMAC. Once released 
into the cytosol, SMAC interacts with XIAP to release XIAP-mediated inhibition of 
caspase-3. Accordingly, in cytosolic extracts of HeLa and HeLa-mycXIAP cells, 
addition of the synthetic SMAC N7 peptide enhanced caspase-3 activity initiated by 
cytochrome c/dATP and restored the caspase-activity blocked by overexpressed 
Figure 7: Cytostatic agent-induced cell death (A) XIAP, actin, Bcl2, SMAC and cytochrome c (cyt. c) 
were detected in total cell extracts of HeLa, HeLa-mycXIAP and HeLa-Bcl2 by Western blot analysis 
using specific antibodies. (B-D) HeLa, HeLa-mycXIAP and HeLa-Bcl2 cell lines were left untreated or 
treated for 24 hours with staurosporine (STS, 0.5 µM), doxorubicin (DOX, 5 µM), etoposide (ETO, 
100 µM), mitoxantrone (MTO, 5 µM), vinblastine (VBL, 50 nM), and vincristin (VCR, 50 nM). Viable 
cell number was determined using the XTT (B) or crystal violet staining assay (CVS). PARP cleavage 
was detected in nuclear extracts using mouse anti-PARP antibody detecting cleaved PARP (D). 
Asterisk indicates nonspecific bands recognized by anti-XIAP antibody. 
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mycXIAP (Fig. 8A). Detailed analyses of the mitochondrial apoptotic pathway in 
HeLa, HeLa-mycXIAP and HeLa-Bcl2 cell lines showed that all tested cytostatic 
agents initiated the mitochondrial release of cytochrome c and SMAC in HeLa and 
HeLa-mycXIAP cells but not in the HeLa-Bcl2 cells with blocked mitochondria 
(Kashkar et al., 2005) (Fig. 8B). The engagement of the mitochondrial apoptotic 
pathway and MOMP by cytostatic drug treatment was predominantly a caspase-
independent process as demonstrated by pre-treatment with the universal caspase 
inhibitor z-VAD (Fig. 8B). In contrast to Bcl2, XIAP was not able to prevent cytostatic 
agent-induced mitochondrial release of SMAC (Fig. 8B) that exerts neutralizing 
activity toward XIAP.  
Figure 8: Cytostatic agents induce caspase-independent SMAC release. (A) Cytosolic extracts of 
HeLa and HeLa-mycXIAP cells were prepared and equal amounts of protein were incubated with 
increasing amount of cytochrome c (0, 0.25, 0.5, and 1 µM) and dATP with or without SMAC N7 
peptide for 15 min at 30°C. Relative caspase-3 activity was measured by using 100 µM Ac-DEVD-
AFC and presented as arbitrary fluorescence units. (B) HeLa, HeLa-mycXIAP and HeLa-Bcl2 cells 
(all 106) were treated with STS (0, 0.25, and 0.5 µM), DOX (0, 2, and 5 µM), ETO (0, 10 and 50 µM), 
MTO (0, 1 and 5 µM), VBL (0, 5 and 20 nM), and VCR (0, 5 and 20 nM) for 12 h. SMAC and 
cytochrome c were detected in cytosolic extracts by specific antibodies. Reprobing for actin ensured 
equal loading of cytosolic extracts. The involvement of caspase activity in cytostatic drugs-induced 
cytchrome c/SMAC release was examined in HeLa cells by z-VAD-FMK (20 µM) co-treatment. 
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If mitochondrial release of SMAC caused neutralization of XIAP, down-regulation of 
SMAC expression should restore XIAPs caspase inhibitory function and confer 
resistance against cytostatic agents. In order to address this issue we specifically 
down-regulated SMAC expression by using small hairpin RNA (shRNA) targeting 
SMAC mRNA (Kashkar et al., 2006). Only HeLa and HeLa-mycXIAP cells expressing 
Figure 9: SMAC knock-down promotes resistance against cytostatic agents and facilitates XIAP anti-
apoptotic function. (A) XIAP, actin, SMAC and cytocherome c were detected in total cell extracts of 
HeLa, HeLa-SMACshRNA, HeLa-mycXIAP and HeLa-mycXIAP-SMACshRNA cells by Western blot 
analysis using specific antibodies against XIAP, cytochrome c, actin (reprobed and merged) and 
SMAC (reprobed and merged). (B) Cells were left untreated or treated for 24 hours with increasing 
concentrations of STS or DOX. The percentage viable cell number was determined using an XTT 
assay. (C) Cells were left untreated or treated for 24 hours with STS (0.5 µM), DOX (5 µM), ETO 
(100 µM), MTO (5 µM), VBL (50 nM), and VCR (50 nM). The percentage viable cell number was 
determined using a CVS assay. Asterisk indicates nonspecific bands recognized by anti-XIAP 
antibody. 
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shRNA against SMAC (HeLa-SMACshRNA and HeLa-mycXIAP-SMACshRNA) 
displayed down-regulated SMAC expression, while scrambled (scr) shRNA (HeLa-
scrshRNA and HeLa-mycXIAP-scrshRNA) remained ineffective (Fig. 9a and 10). The 
specificity of the SMAC knockdown was revealed by unaltered cytochrome c, Bcl2, 
XIAP, and actin expression (Fig. 9A and Fig. 10). We next examined whether SMAC 
down-regulation results in decreased susceptibility of cells to cytostatic agents. 
HeLa-SMACshRNA and HeLa-mycXIAP-SMACshRNA but not HeLa-scrshRNA 
showed markedly reduced susceptibility to STS and DOX treatment compared to 
their parental counterparts HeLa and HeLa-mycXIAP, respectively (Fig. 9B). This is 
additionally confirmed by a separate cytotoxicity assay and holds true for other 
cytostatic drugs demonstrating the key regulatory role of SMAC in cytostatic agent-
induced cell death (Fig. 9C and Fig. 11).  
 
 
Fig. 10: Western blot analysis of cell lines used in 
this work. XIAP, actin, Bcl2, SMAC and 
Cytochrome c were detected in total cell extracts 
of HeLa, HeLa-scrshRNA, HeLa-SMACshRNA, 
HeLa-XIAPshRNA, HeLa-Bcl2, HeLa-Bcl2-
scrshRNA, HeLa-Bcl2-XIAPshRNA, HeLa-
mycXIAP, HeLa-mycXIAP-scrshRNA, and HeLa-
myXIAP-SMACshRNA cell lines by Western blot 
analysis using specific antibodies. Asterisk 
indicates nonspecific bands recognized by anti-
XIAP antibody.
Fig. 11: Expression of scrshRNA does not influence cytotoxic activity of cytostatic agents. Cells were 
left untreated or treated for 24 hours with indicated concentrations of STS and DOX. The percentage 
viable cell number was determined using a CVS assay.  
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It is important to note that SMAC knock-down did not cause any alteration in 
cytochrome c release after cytostatic drug treatment as shown in Fig. 12. The lack of 
Figure 12: SMAC knock-down does not influence mitochondrial release of cytochrome c. (A) Cells 
were treated with STS (0.5 µM) for 12 h. SMAC and cytochrome c were detected in cytosolic extracts 
by specific antibodies. Reprobing for actin ensured equal loading of cytosolic extracts. PARP 
cleavage was detected in nuclear extracts using mouse anti-PARP antibody detecting cleaved 
PARP. (B) IF analysis of SMAC and cytochrome c release after STS and DOX treatment in HeLa and 
HeLa-SMACshRNA cell lines. Cells were left untreated or treated with STS (0.5 µM) or DOX (5 µM) 
for 8h. SMAC and cytochrome c were detected by specific primary and secondary Alexa Fluor 568-
conjugated antibodies (red). Nuclei were co-stained with Hoechst 33258. 
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SMAC in HeLa-SMACshRNA resulted in blockade of caspase activity by XIAP as 
demonstrated by incomplete PARP cleavage (Fig. 12A) and failure of nuclear 
fragmentation (Fig. 12B). This effect was significantly enhanced in HeLa-mycXIAP-
SMACshRNA lacking SMAC expression and overexpressing XIAP as shown by 
complete blockade of PARP cleavage (Fig. 12A).  
 
Correspondingly, XIAP knock-down in HeLa-SMACshRNA cells restored their 
apoptotic capability and enhanced the cytotoxicity mediated by STS (Fig. 13). HeLa-
SMACshRNA cells were transiently transfected with DNA constructs containing 
XIAPshRNA or scrshRNA expression cassettes which in addition co-expressed 
EGFP to visualize the transfected cells. As shown in Fig. 13A, XIAP expression was 
specifically down-regulated in the HeLa-SMACshRNA cells transfected with EGFP-
XIAPshRNA but not with EGFP-scr-shRNA. Immunofluorescence (IF) analysis 
revealed nuclear fragmentation as a sign of the ongoing apoptotic process after STS 
treatment in HeLa-SMACshRNA cells transiently transfected with EGFP-XIAPshRNA 
but not in untransfected cells or cells transfected with EGFP-scr-RNA (Fig. 13B). 
Correspondingly, HeLa-SMACshRNA cells depleted of XIAP displayed increased 
susceptibility to STS (Fig. 13C). IF analysis of cytochrome c showed that XIAP down-
regulation did not facilitate cytochrome c release nor did it promote any nuclear 
fragmentation in untreated cells (Fig. 13B) underscoring the interplay between XIAP 
expression and mitochondrial SMAC release in modulating caspase activity initiated 
by cytosolic cytochrome c. Taken together, these data suggest that the XIAP-
mediated chemoresistance is SMAC dependent.  
 
Figure 13: XIAP knock-down restores inefficient apoptosis in HeLa-SMACshRNA cells. HeLa-
SMACshRNA cells were transiently transfected with DNA constructs encoding EGFP together with 
XIAPshRNA or scrshRNA expression cassettes. (A) After 48 hours cell extracts were prepared and 
XIAP, actin and GFP were detected in Western blot analysis using specific antibodies. (B) Cells were 
left untreated or treated with STS (0.5 µM) for 8h. Cytochrome c was detected by specific primary 
and secondary Alexa Fluor 568-conjugated antibodies (red). Nuclei were co-stained with Hoechst 
33258. Transfected cells appeared green by co-expression of EGFP. (C) Viability was 
microscopically determined by evaluating >300 EGFP expressing cells. The percentage of viable 
cells was calculated relative to the total cell number. Asterisk indicates nonspecific bands recognized 
by anti-XIAP antibody. 
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The Role of XIAP in chemoresistant Hodgkin Lymphoma (HL) 
derived B-cell lines 
One of the central piece of evidence validating XIAP as a chemoresistance factor is 
derived from observations that XIAP targeting markedly enhanced the cytotoxic 
activity of different cytostatic drugs in different tumor types (Schimmer et al., 2006). 
The malignant Hodgkin and Reed-Sternberg (H-RS) cells of Hodgkin lymphoma (HL) 
are germinal center B cells with a dysfunctional apoptotic machinery (Marafioti et al., 
2000). Previous results demonstrated an elevated expression of XIAP in H-RS cell 
lines and primary tumor tissues as a hallmark of HL (Akyurek et al., 2006; Kashkar et 
al., 2003).  
As shown in Figure 14, HL B-cell lines L428 and L591 were resistant to staurosporine 
(STS), etoposide, doxorubicin, vinblastine, and cisplatin. In contrast, treatment of 
Jurkat T cells or the control B-cell line L1309 with all cytotoxic agents resulted in cell 
death (Figure 14A) associated with PARP cleavage (Figure 14B) indicating an 
apoptotic cell death. If XIAP is the key mediator of chemoresistance in HL B-cells, 
knock-down of XIAP by RNAi should sensitize HL cells to cytotoxic drugs. XIAP 
expression was specifically down-regulated by generating HL cell lines stably 
Figure 14: Chemoresistance of HL B-cell lines against cytostatic agents. Control B-cell line L1309, 
control Jurkat T-cell line, and HL B-cell lines L428 and L591 were treated with staurosporine (0.5 
µM), etoposide (50 µM), doxorubicin (1 µM), vinblastine (0.2 µM), or cisplatin (200 µM) and incubated 
for 24 hours. (A) Viability was assayed by XTT test. The means ± SD are from 3 individual 
experiments performed in triplicate. (B) PARP cleavage was detected in nuclear extracts by mouse 
anti-PARP antibody. 
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Figure 15: Knock-down of XIAP by RNAi sensitizes HL B-cell lines for cytostatic agents. (A) cIAP2, 
XIAP, caspase-3, SMAC, cIAP1, and actin were detected in total cell extracts of L428, L428-scr-
shRNA, L428-XIAP-shRNA, L591, L591-scr-shRNA, and L591-XIAP-shRNA by Western blot analysis 
using specific antibodies. (B) Quantitative analysis of panel A. Graphs of mean band intensity of 
XIAP from Western blot images were acquired on an Alpha Innotech documentation station. All 
values were normalized to actin expression levels and are presented as percentage of the mean 
levels in untreated cells (100%). The SD values were calculated from 3 individual experiments. (C-D) 
HL B-cell lines L428, L428-scr-shRNA, L428-XIAP-shRNA, L591, L591-scr-shRNA, and L591-XIAP-
shRNA were left untreated or treated for 24 hours with STS (0.5 µM), etoposide (50 µM), doxorubicin 
(1 µM), vinblastine (0.2 µM), or cisplatin (200 µM). Viable cell number was determined using an XTT 
assay (C). PARP cleavage was detected in nuclear extracts by mouse anti-PARP antibody (D). 
expressing small hairpin RNA (shRNA) targeting XIAP mRNA using lentiviral gene 
transfer.  
As shown in Figure 15A, only HL cells expressing shRNA against XIAP (L428-
XIAPshRNA and L591-XIAPshRNA) displayed down-regulated XIAP expression (up 
to 82% reduction; Figure 15B), while scrambled (scr) shRNA (L428-scrshRNA and 
L591-scrshRNA) remained ineffective. The specificity of XIAP knockdown was 
revealed by unaltered expression of caspase 3, SMAC, cIAP1, cIAP2, and actin 
(Figure 15A). We finally examined whether XIAP down-regulation results in increased 
susceptibility to cytotoxic drugs by analyzing cell viability and PARP cleavage. As 
shown in Figure 15C-D, cytotoxic agents induced significantly increased cell death 
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and promoted PARP cleavage in L428-XIAPshRNA and L591-XIAPshRNA cell lines 
lacking XIAP expression. As already shown in Figure14, parental L428 and L591 or 
derivatives expressing scrambled shRNA (Figure 15D) were only partially affected 
and did not show any PARP cleavage. Apparently, selective downregulation of XIAP 
enhances chemosensitivity in HL cells and promotes caspase activity. 
 
The question remaining and raised now is whether XIAP knock-down completely 
reactivated the dysfunctional apoptotic machinery of HL cells which might strongly 
indicate the central role of XIAP as a chemoresistance factor in these tumor cells. As 
shown in Fig. 16A, although potentiating some caspase activity and significantly 
upregulating cytotoxicity mediated by high-dose STS (compare L591-scrshRNA and 
L428-scrshRNA with L591-XIAPshRNA and L428-XIAPshRNA, respectively), XIAP 
knock-down in HL cell lines failed to completely restore the cytotoxicity initiated by 
STS (compare Jurkat control cell line with L591-XIAPshRNA and L428-XIAPshRNA 
treated with 0.5 µM STS) (Fig. 16A). Mitochondria as the central molecular 
mechanism determining the chemosusceptibility (Reed, 1995) have been previously 
shown to be blocked in HL cells through an as yet unknown mechanism (Kashkar et 
al., 2002). Correspondingly, analysis of the STS-induced mitochondrial apoptotic 
pathway including Bax activation and cytochrome c release revealed that XIAP 
knock-down did not restore the defective mitochondria in HL cells (Fig. 16B) and thus 
could not completely restore the cytotoxic effect of STS. In contrast to control cells, 
only small amounts of cytochrome c were detected in the cytosolic fractions of HL 
cells after high-dose STS treatment which might be a result of intracellular organelle 
injury without involving Bax action (Fig. 16C). Analysis of caspase-3 activity in a cell-
free system using exogenous cytochrome c revealed that the lack of XIAP in L591-
XIAPshRNA and L428-XIAPshRNA significantly facilitated caspase activity (Fig. 
16D). Thus, small amounts of cytosolic cytochrome c in HL cells depleted of XIAP 
might be capable to initiate some caspase activation which underlies the enhanced 
STS-induced cytotoxicity (Fig. 15A&C). The results obtained revealed that XIAP 
knock-down reproduced the effect of cytosolic SMAC (Fig. 16D) and thus restored, 
only in part, the mitochondrial apoptotic function. Moreover, these data suggest that 
the chemoresistant phenotype in HL cells is not entirely a result of elevated XIAP 
expression and hence might not be completely restored by XIAP targeting.  
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This issue was additionally addressed by XIAP knock-down in chemosensitive HeLa 
and chemoresistant HeLa-Bcl2 cell lines (HeLa-XIAPshRNA and HeLa-Bcl2-
Figure 16: XIAP down-regulation does not restore the mitochondrial apoptotic pathway in H-RS cell 
lines. (A-C) Jurkat, Jurkat-Bcl2, L591-scrshRNA, L428-scrshRNA, L591-XIAPshRNA and L428-
XIAPshRNA cells were left untreated or treated with indicated increasing concentrations of STS. (A) 
After 12 hours, cytosolic extracts were isolated and caspase-3 activity was measured using DEVD-
AFC as substrate. Cell death was assessed by trypan blue exclusion after 24 hours. Each time point 
represents the average of triplicates. (B) Activated Bax was immunoprecipitated in CHAPS total cell 
lysates after 12 hours using the conformation-specific anti-Bax antibody 6A7, followed by Western 
blotting using anti-human Bax antiserum. (C) Cytosolic cytochrome c was detected in cytosolic 
fractions of cells after 12 hours STS treatment using anti-cytochrome c antibody. Reprobing for actin 
ensured equal loading of cytosolic extracts. (D) Cytosolic extracts of L591-scrshRNA, L428-
scrshRNA, L591-XIAPshRNA and L428-XIAPshRNA cells were prepared and equal amounts of 
protein were incubated with increasing amount of cytochrome c (0, 0.25, 0.5, and 1 µM) and dATP 
with or without SMAC N7 peptide for 15 min at 30°C. Relative caspase-3 activity was measured by 
using 100 µM Ac-DEVD-AFC and presented as arbitrary fluorescence units. The experimental values 
represent mean ± SD values from at least 3 individual experiments performed in triplicate. 
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XIAPshRNA) (Fig. 17A). In a detailed dose response analysis to STS treatment XIAP 
knock-down occurred to be sensitizing HeLa-Bcl2 only at high-dose STS-treatment 
(0.5-2 µM) (Fig. 17B). This was confirmed in a separate cytotoxicity assay and holds 
true for all cytostatic agents tested (Fig. 17C). Although XIAP targeting enhanced the 
cytotoxic activity of variety of cytostatic drugs (compare HeLa with HeLa-XIAPshRNA 
or HeLa-Bcl2 with HeLa-Bcl2-XIAPshRNA in Fig. 17C), it failed to restore the 
chemosensitivity in chemoresistant HeLa-Bcl2 cell line (compare HeLa with HeLa-
Bcl2-XIAPshRNA). Detailed analysis of the mitochondrial apoptotic pathway after 
STS treatment revealed that XIAP knock-down did not result in greater integration of 
mitochondria in STS-induced cell death in HeLa cell lines nor reactivated the blocked 
mitochondrial apoptotic machinery in HeLa-Bcl2 cell lines (Fig. 17D). Similar to the 
results obtained in HL cells, analysis of caspase-3 activity in a cell free system 
revealed that the lack of XIAP in HeLa-XIAPshRNA and HeLa-Bcl2-XIAPshRNA 
significantly enhanced caspase activity by exogenous addition of cytochrome c (Fig. 
17E).  
Together these data demonstrated that XIAP targeting does not diminish 
chemoresistance mediated by defective mitochondria based on the essential need of 
caspase proteolytic activity initiating events like cytochrome c release which could 
not be restored by XIAP targeting.  
Figure 17: XIAP knock-down enhances cytotoxicity in HeLa and HeLa-Bcl2 cells. (A) XIAP, actin, 
Bcl2, SMAC and cytochrome c were detected in total cell extracts of HeLa, HeLa-XIAPshRNA, HeLa-
Bcl2 and HeLa-Bcl2-XIAPshRNA cells by Western blot analysis using specific antibodies. (B) Cells 
were left untreated or treated for 24 hours with increasing concentrations of STS. The percentage 
viable cell number was determined using XTT assay. (C) Cells were left untreated or treated for 24 
hours with STS (0.2 and 2 μM), DOX (2 and 5 μM), ETO (20 and 100 μM), MTO (1 and 5 μM), VBL 
(10 and 50 nM), and VCR (10 and 50 nM). The percentage viable cell number was determined using 
CVS assay. (D) Cells were left untreated or treated with increasing concentrations of STS. Activated 
Bax was immunoprecipitated in CHAPS total cell lysates after 12 hours using the conformation-
specific anti-Bax antibody 6A7, followed by Western blotting using anti-human Bax antiserum. Bcl2, 
Bax, actin and XIAP were detected in total cell lysates using specific antibodies. Cytochrome c was 
detected in cytosolic fractions of cells after 12 hours STS treatment using an anti-cytochrome c 
antibody. PARP cleavage was detected after 24 hours in nuclear extracts by mouse anti-PARP 
antibody. (E) Cytosolic extracts of HeLa, HeLa-XIAPshRNA, HeLa-Bcl2 and HeLa-Bcl2-XIAPshRNA 
cells were prepared and caspase activity was assessed as in Fig. 2A. Asterisk indicates nonspecific 
bands recognized by anti-XIAP and ant-SMAC antibodies. 
Results 
42 
 
 
XIAP targeting completely restored granzyme B-mediated apoptosis 
in HL 
The crucial event in cytostatic drug-induced apoptosis is the mitochondrial outer 
membrane permeabilization (MOMP) with the subsequent release of multiple pro-
apoptotic factors including cytochrome c, initiating caspase proteolytic activity. 
Mitochondrial malfunction therefore results in a lack of initiation of the caspase 
cascade in response to cytostatic drug treatment and has been viewed as the central 
molecular mechanism conferring chemoresistance in tumor cells (Reed, 1995). In 
contrast to cytostatic drugs, immune effector cell-induced apoptosis does not 
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primarily involve mitochondria to initiate caspase proteolytic activity. They trigger an 
initial activation of executioner caspases provided by caspase-8 or granzyme B 
(grzB), which can be blocked by XIAP over expression. Correspondingly, previous 
results demonstrated a defective grzB-mediated cytotoxicity in HL cells (Kashkar et 
al., 2006). One hallmark of grzB-mediated cytotoxicity is a proapoptotic amplification 
loop involving mitochondrial release of SMAC to overcome the inhibitory effect of 
XIAP (Goping et al., 2003; Sutton et al., 2003). We, therefore, investigated the 
capability of grzB to initiate mitochondrial release of proapoptotic proteins, SMAC 
and cytochrome c.  
 
As shown in Figure 18A, grzB/Ad treatment of HL cells did not result in efflux of 
SMAC and cytochrome c into the cytoplasm, whereas SMAC and cytochrome c were 
detected in cytosolic extracts of grzB/Ad-treated L1309 B cells and Jurkat T cells. 
These results suggest a defective grzB-mediated mitochondrial apoptotic pathway in 
HL cells. In cytosolic extracts of untreated L428 HL cells, cytochrome c/dATP or grzB 
only partially initiated caspase-3 activity. Addition of the SMAC N7 peptide restored 
caspase-3 activity initiated by cytochrome c/dATP treatment. Similarly, grzB-induced 
caspase-3 activity was significantly increased upon SMAC treatment (Figure 19a).  
Figure 18: GrzB fails to initiate the release of mitochondrial proapoptotic factors (A) Control L1309 B 
cells, Jurkat T cells, and L428 cells (all 106) were treated with adenovirus at an moi of 100 with or 
without 600 ng/mL grzB and incubated for 2 hours at 37°C. SMAC and cytochrome c were detected 
in cytosolic extracts by respective specific antibodies. Reprobing for actin ensured equal loading of 
cytosolic extracts. (B) Isolated postnuclear fractions (cytoplasm and mitochondria) from Jurkat T cells 
and L428 HL cells were treated for 30 minutes at 30°C with grzB (200 ng). After centrifugation, 
supernatants were analyzed by Western blotting with monoclonal antibodies specific for cytochrome 
c, SMAC, and actin. 
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The potency of SMAC to support grzB-mediated cell death was further examined by 
expression of cytosolic mature SMAC lacking the mitochondrial targeting sequence, 
which was accomplished by using the ubiquitin (Ub) fusion system previously 
described by Hunter et al. The Ub-SMAC fusion protein contains an amino terminal 
human Ub fused to human mature SMAC, which when expressed in the cytosol will 
be immediately cleaved by an Ub-specific protease to generate the correct AVPI 
NH2-terminus of SMAC critical for interaction with XIAP. In addition, a dsRed 
fluorescence tag was added to the COOH-terminus to allow distinction of the 
transfected cells (Figure 19b). When L428 HL cells were transiently transfected with 
DNA constructs expressing Ub-SMAC-dsRed or Ub-dsRed as a control, all fusion 
proteins displayed diffused, cytoplasmic distribution patterns (Figure 19c). The 
apoptotic capability of grzB was analyzed by staining of nuclei using Hoechst (blue), 
visualizing nuclear fragmentation as a sign of apoptosis. Only expression of mature 
SMAC contributed to nuclear fragmentation in grzB/Ad-treated L428 HL cells. No 
nuclear fragmentation was observed in HL cells expressing Ub-dsRed lacking SMAC 
sequences. 
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The finding that SMAC restored grzB-induced caspase activity suggested that XIAP 
is a key inhibitor of grzB-mediated apoptosis in HL cells. If XIAP is the central 
determinant of resistance against grzB-mediated cell death, down-regulation of XIAP 
expression should completely restore grzB-induced apoptosis and cytotoxicity in HL 
cells. Depletion of XIAP in L428 HL cells (L428-XIAPshRNA) resulted in an increased 
caspase-3 activity after grzB/Ad treatment. Concomitantly, down-regulation of XIAP 
restored grzB-mediated cytotoxicity in L428-XIAPshRNA cell line (compare to grzB-
mediated caspase-3 activity and cytotoxicity in control cell line), whereas grzB/Ad 
treatment in L428 and L428-scrshRNA produced only minor cytotoxicity (Figure 20). 
Unlike chemotherapeutic agents, XIAP targeting resulted in complete reactivation of 
the apoptotic machinery in response to grzB treatment regardless of mitochondrial 
functional state and the data provided are completely in line with the current model of 
XIAP action (Goping et al., 2003; Kashkar et al., 2006; Sutton et al., 2003; Wilkinson 
et al., 2004). 
Figure 19: SMAC enhances grzB-induced caspase activity and cell death. (A) Cytosolic extracts of 
L428 HL cells were prepared, and the protein content was normalized (10 µg/µL). Caspase activation 
was initiated by addition of cytochrome c/dATP or recombinant grzB (20 ng) in the absence or 
presence of SMAC N7 peptide (10 µM). After incubation for 1 hour at 30°C, relative caspase-3 
activity was measured by using DEVD-AFC as substrate. (B) Only mature SMAC (without its MTS) 
was amplified by PCR, fused to human ubitiquin1 as previously described (Hunter et al., 2003) and 
cloned into pDS-Red expression vector (Invitrogen). As a control only ubiquitin1 was cloned into 
pDS-Red vector. (C) L428 HL cells were transiently transfected with Ub-SMAC-dsRed or Ub-dsRed 
(red). Cells were left untreated or treated with grzB/Ad. After fixation, nuclei were stained (Hoechst 
33258) (blue). 
Figure 20: XIAP down-regulation restores apoptotic capability of grzB in HL cells L1309 B cells, 
Jurkat T cells, or HL cells L428, L428-scr-shRNA, L428-XIAPshRNA (all 106) were left untreated or 
treated with adenovirus (moi of 100), isolated human grzB (600 ng), or adenovirus (moi of 100) plus 
isolated human grzB (600 ng). (A) Cell death was determined after 4 hours. (B) After 2 hours, 
cytosolic extracts were isolated and caspase-3 activity was measured using DEVD-AFC as 
substrate. Cell death was assessed after 4 hours. 
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Discussion 
In this study, the impact of elevated XIAP expression on the chemoresistance of 
tumor cells was examined. Using HeLa cells stably over expressing myc-tagged 
XIAP the present data showed that XIAP over expression alone does not confer 
chemoresistance. The results demonstrated that the expression and the 
mitochondrial release of SMAC during cytostatic drug treatment determine the 
potency of XIAP as a chemoresistance factor. Although increased cytotoxic activity of 
different cytostatic drugs was observed, XIAP targeting failed to restore 
chemosensitivity in chemoresistant HL cells indicating limited involvement of XIAP in 
chemoresistance. Unlike chemotherapeutic agents, XIAP targeting resulted in 
complete reactivation of the apoptotic machinery in response to grzB treatment 
regardless of the functional state of mitochondrial.  
As a prominent member of the IAP protein family with the most potent caspase 
inhibitory capacity (Eckelman et al., 2006) XIAP was identified as a major 
chemoresistant factor and has received great attention in the last decade as a 
possible therapeutic target in cancer (Schimmer et al., 2006). Studies describing 
XIAP function were carried out using cell-free systems and recombinant proteins 
(Deveraux et al., 1998; Deveraux et al., 1997), yeast systems (Silke et al., 2001; 
Silke et al., 2002) or transient-overexpression of XIAP in intact cells (Deveraux et al., 
1998; Silke et al., 2001) but disregarding the central role of mitochondria in 
controlling XIAP function. Accordingly, the results obtained in these studies are 
limited to describing the capacity of XIAP in inhibiting cell death and fail to properly 
examine the potency of XIAP in the context of regulatory circuits. As previously 
shown (Du et al., 2000), the caspase inhibitor XIAP is under stringent control of 
mitochondrial SMAC. Strikingly, all chemotherapeutic agents tested in this work were 
capable of inducing mitochondrial SMAC release independent of caspase activity, 
even after XIAP overexpression (Fig. 8). The caspase inhibitory function of 
overexpressed XIAP is completely abrogated by cytosolic SMAC and no 
cytoprotective effect of XIAP expression can be detected in the presence of SMAC 
(Fig. 7). Thus, elevated XIAP expression alone does not confer chemoresistance, nor 
can the XIAP expression level be used to predict the chemosensitivity of a particular 
tumor cell.  
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From a therapeutic perspective it is important that the expression level of the target 
molecule correlates with patient outcomes. The prognostic value of XIAP levels in 
cancer patients varies among different tumors. Whereas in patients with clear-cell 
renal carcinoma and acute myeloid leukemia (AML) (Tamm et al., 2004b) increased 
XIAP expression is associated with decreased survival, several recent reports 
demonstrated no correlation or even counterintuitive direct association between XIAP 
expression and favorable clinical outcome (Carter et al., 2003; Ferreira et al., 2001; 
Hwang et al., 2008; Liu et al., 2001; Seligson et al., 2007). For example, in patients 
with radically resected non-small-cell lung carcinoma (Ferreira et al., 2001), prostate 
cancer (Seligson et al., 2007) as well as in a mouse prostate cancer model (Hwang 
et al., 2008) high levels of XIAP expression in the tumor were associated with 
prolonged overall survival. It is not entirely clear why overexpression of XIAP may be 
associated with a good prognosis, but a few possibilities can be considered. First, 
XIAP is just one of the eight currently identified IAP family members and a sum or 
weighted sum of all IAPs may be required to assess the impact IAPs have on patient 
outcome. Alternatively, post-translational modifications of XIAP may affect XIAP 
function without affecting the level of expression. Also, the high levels of XIAP 
expression may be able to compensate for an increased propensity for apoptosis. 
Under these circumstances, XIAP may not be fully protective and the cells may be 
more susceptible to chemotherapy (Schimmer et al., 2006). Thus, regarding the 
delicate balance between the expression of XIAP and SMAC in different cell types 
and the fact that mitochondria are variably targeted by different stimuli, analyses of 
the mitochondrial function and the relative expression level of XIAP and SMAC are 
essential for predicting the chemosensitivity of particular tumors in response to 
specific cytostatic agents. 
 
In previous reports XIAP was shown to be overexpressed in Hodgkin and Reed-
Sternberg (H-RS) cells of Hodgkin lymphoma (HL) (Kashkar et al., 2003) and XIAP 
has been suggested to be a key mediator of apoptosis resistance in HL cells 
(Akyurek et al., 2006; Kashkar et al., 2003). The observations that the down-
regulation of XIAP by RNAi enhanced the cytotoxicity of a variety of cytostatic drugs 
(Fig. 15) and the fact that XIAP is strongly expressed in most HL cases argued for 
XIAP as the possible chemoresistance factor in HL B cells. Indeed, one of the central 
pieces of evidence validating XIAP as a chemoresistance factor is derived from 
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observations that XIAP targeting markedly enhanced the cytotoxic activity of different 
cytostatic drugs in a variety of tumor types (Schimmer et al., 2006). In response to 
diverse intracellular damage signals, including those evoked by cancer 
chemotherapy, the decision to undergo apoptosis is mainly determined by the 
mitochondria. The crucial event then is the mitochondrial outer membrane 
permeabilization (MOMP) with the subsequent release of multiple pro-apoptotic 
factors including cytochrome c and SMAC, simultaneously initiating and facilitating 
caspase activity, respectively. Mitochondrial malfunction therefore results in a lack of 
initiation and regulation of the caspase cascade in response to cytostatic drug 
treatment and has been viewed as the central molecular mechanism conferring 
chemoresistance in tumor cells (Reed, 1995). In HL tumor cells XIAP targeting 
enhanced the cytotoxicity of cytostatic agents, yet did not completely restore the 
apoptotic response. Indeed, XIAP down-regulation failed to initiate the proteolytic 
caspase activation, yet potentiated caspase activity driving cytostatic drug-induced 
apoptosis (Fig. 16 & 17). These findings can be explained by defective mitochondrial 
apoptotic pathways characteristic of HL cells (Kashkar et al., 2002). 
 
Strikingly, the multifaceted antiapoptotic barrier of HL cells could be disrupted by 
single-step anti-XIAP strategies in grzB-mediated apoptosis. In contrast to cytostatic 
drugs, death receptor- or immune effector cell-induced apoptosis does not primarily 
involve mitochondria to initiate caspase proteolytic activity. Unlike chemotherapeutic 
agents, they trigger an initial activation of executioner caspases provided by 
caspase-8 or grzB, which can be blocked by XIAP overexpression (Fig. 21). 
Consequently, XIAP targeting in the contest of grzB resulted in complete reactivation 
of the apoptotic machinery regardless of mitochondrial functional state (Fig. 15). 
Apoptotic resistance of HL cells was completely abrogated by depletion of XIAP in HL 
cells not only sufficed to restore grzB-mediated caspase-3 activation and cell death 
but also sensitized HL cells for CTL-mediated cytotoxicity (Kashkar et al., 2006), 
indicating that XIAP is the main determinant of HL cell resistance to CTL-mediated 
cytolysis. These observations further underline the role of mitochondria, in particular, 
the mitochondrial release of SMAC to inhibit XIAP action as an important regulator of 
grzB-induced caspase-3 activation and is completely in line with the current model 
describing grzB-mediated cytotoxicity (Goping et al., 2003; Kashkar et al., 2006; 
Sutton et al., 2003; Wilkinson et al., 2004).  
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The original discovery and characterization of viral IAP proteins demonstrated the 
involvement of this protein family in the apoptotic process. Further structural and 
functional studies have provided insight into the mechanism by which XIAP inhibits 
caspases and have demonstrated unique functional properties for the BIR domains 
directly binding and inhibiting caspases. However, BIRs mediate interactions with 
molecules not directly involved in signaling for, or executing, the apoptotic program. 
Unlike BIR2 and BIR3, the BIR1 domain of XIAP, c-IAP1, and c-IAP2 does not bind 
caspases or IBM proteins. Rather, it functions in several signaling pathways via 
oligomerization of binding partners. For example, overexpressed XIAP BIR1 has 
been shown to interact with TAB1, the TGF-b activating kinase 1 (TAK1) associating 
subunit 1; an event that has been suggested to be important for the XIAP-induced 
MAPK kinase kinase activation mediated by TAK1 and TGF-β signaling (Lu et al., 
Figure 21: The role of XIAP in apoptosis. Induction of the extrinsic apoptotic pathway via the death 
receptor leads to the activation of caspase-8, following activation of caspase-3 and ongoing 
apoptosis. Caspase-3 could also directly activated by Granzyme B, which enters the cell by perforin. 
Protection against apoptosis is mediated by XIAP which binds and inhibits caspase-3 (and also 
caspase-9). Indirect activation of mitochondria initiated by caspase-8 or Granzyme B leads to the 
release of proapoptotic factors from the inner membrane space into the cytosol like cytochrome c 
which activates caspase-9 and functions as an amplification loop. More important, mature SMAC is 
also released from mitochondria. Binding to XIAP results in the release of caspase-9 and caspase-3, 
underlining the apoptotic resistance mediated by XIAP overexpression in SMAC deficient cells or 
cells with disturbed mitochondrial release of SMAC. 
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2007). Additionally, BIRs mediate binding between members of the IAP family itself. 
For example, the XIAP BIR1 and BIR3 domains interact with the single BIR of 
survivin, and upon being signaled for apoptosis, these molecules form higher-order 
complexes (Dohi et al., 2004). In addition to the family-defining BIRs, some IAPs 
contain another more widely distributed region called a RING domain. RING domains 
often function as modules that confer ubiquitin protein ligase (E3) activity and, in 
conjunction with an ubiquitin activating enzyme (E1) and an ubiquitin conjugating 
enzyme (E2), catalyze the transfer of ubiquitin to target proteins (Lorick et al., 1999). 
All known RING-containing IAPs including XIAP have E3 activity, and the range of 
substrates includes molecules involved in apoptosis and signaling, and even 
themselves in a homo- or heterotypic fashion. For example, XIAP is known to 
activate NF-κB and JNK via its E3 ubiquitin ligase activity of the RING domain and 
can be dissociated from the caspase inhibitory effects of XIAP. Thus, XIAP targeting 
by XIAP knock-down could also induce apoptosis by blocking NF-κB activation and 
not only by relieving caspase activity. Furthermore, almost all structural knowledge 
about BIR-protein interactions has been obtained with isolated domains and only a 
few biochemical approaches have tried to unravel the complex nature of the 
intermolecular interactions of these domains in full-length IAP molecules. For 
example, SMAC binding to XIAP BIR2 and BIR3 gives rise to changes that affect 
BIR1 interactions, in particular preventing full-length XIAP BIR1/TAB1 interactions 
(Lu et al., 2007). Unlike full-length SMAC, dimeric SMAC peptides (dAVPI) fail to 
disrupt XIAP/TAB1 interactions, suggesting that the inhibitory effect is likely a result 
of sterical exclusion rather than direct competition (Lu et al., 2007). Evidence also 
implicates XIAP as regulators of the cell cycle. Taken together, these observations 
indicate the complex nature of IAPs and demonstrate the fundamental need for 
further investigation of IAPs addressing their real physiological function.  
 
Although the prognostic significance of elevated XIAP levels is still not clear, 
research efforts have lately been focusing on the development of drugs targeting 
XIAP in cancer and are currently being evaluated in clinical trials (reviewed by 
Schimmer et al., 2006 and Srinivasula and Ashwell, 2000).  However, the data 
presented here showed that elevated XIAP expression alone does not confer 
chemoresistance to 6 different chemotherapeutic agents (3 different classes targeting 
kinases, DNA or microtubules) and therefore may not represent the target to 
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overcome chemoresistance. In addition, the observation appropriate that knockout 
mice for XIAP, cIAP1, and cIAP2 show no obvious phenotype (Conte et al., 2006; 
Conze et al., 2005; Harlin et al., 2001) and the fact that IAPs are involved in mitotic 
chromosome segregation, cellular morphogenesis, copper homeostasis, and 
intracellular signaling (reviewed by Srinivasula and Ashwell, 2008) may argue for the 
nonapoptotic function of XIAP and exclude the impact of XIAP on mammalian 
cancer. However, despite the initial absence of major abnormalities, a few stimulus-
specific and tissue-dependent defects in apoptosis have been identified in XIAP 
knockout mice (Potts et al., 2005; Potts et al., 2003). Surprisingly, the severe 
consequences of XIAP mutations in humans (X-linked lymphoproliferative syndrome) 
(Nichols et al., 2005) indicate that although unlikely, it is possible that XIAP has 
acquired functions in humans that it does not have in mice. It is also possible that in 
mice, but not in humans, other IAPs perform XIAP-overlapping activities (reviewed by 
Srinivasula and Ashwell, 2008). Furthermore, experiments evaluating both stable 
XIAP overexpression and knock-down of SMAC (Fig. 9) demonstrated that SMAC 
plays a critical role in determining the chemosensitivity of tumor cells overexpressing 
XIAP. These data clearly showed that XIAP overexpression significantly inhibited 
cytotoxicity mediated by chemotherapeutic drugs only in cells lacking SMAC (Fig. 9, 
compare to Bcl2-mediated chemoresistance in Fig. 7). Thus, XIAP may initiate 
chemoresistance in cells lacking SMAC expression or functional mitochondria, a 
phenomenon that could potentially occur in a tumor cell. 
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